MannKind Corp Q1 2025 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Olivia Brayer - Cantor Fitzgerald - Analyst : Hi, good morning, guys. Thank you for the question. Mike, I wanted to follow up on your IPF study, especially as it relates to endpoints. Maybe it's a little premature to ask, but are you guys looking to measure FVC in that study? And maybe just any comments around whether you're hoping to actually show improvement from baseline versus the delta from the placebo arm? And then also if there's anything you can tell us with respect to dose levels? And then I've got a follow-up question on Tyvaso.

Question: Olivia Brayer - Cantor Fitzgerald - Analyst : Okay. Understood. And then obviously, Tyvaso IPF data coming up in a few months for the nebulizer. I know they've talked about a potential bridging study for DPI. Do you know at this point if that would be an inferiority study between the two DPI and the nebulized formulation? And anything you can tell us at this point in terms of timing around when that could kick off and how long that could realistically take? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 08, 2025 / 1:00PM, MNKD.OQ - Q1 2025 MannKind Corp Earnings Call

Question: Olivia Brayer - Cantor Fitzgerald - Analyst : Okay, understood. Helpful. Thank you, guys. Congrats on the quarter.

Question: Yun Zhong - Wedbush - Analyst : Hi, good morning. Thank you very much for taking the question. And so my question is on Afrezza. It's very encouraging to see a higher increase in NRx versus TRx. Would you attribute that to maybe higher promotional activity or new data or the combination of both? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 08, 2025 / 1:00PM, MNKD.OQ - Q1 2025 MannKind Corp Earnings Call

Question: Yun Zhong - Wedbush - Analyst : Would you say the strategy will be the same for pediatric patient?

Question: Yun Zhong - Wedbush - Analyst : Right. So going into pediatric potential launch and what would be your strategy just like the same as you took for adult patient?

Question: Yun Zhong - Wedbush - Analyst : Thank you very much.

Question: Anthony Petrone - Mizuho Securities - Analyst : Hi, thanks and congrats on a strong start to the year here. I'll start with one on pediatric Afrezza and then move over to the pipeline. On pediatric Afrezza, maybe, Mike, can you give us an idea when you think about how that patient population behaves and your thoughts on adherence? Obviously, with peds, you have a caregiver, tends to be a slightly more diligent sort of patient population relative to adult. So maybe just your thoughts here on what adherence looks like in pediatric diabetes and really what the uptake could be? I would imagine maybe there's a potential for a more rapid uptake in peds versus adults. And I'll have a follow-up.

Question: Anthony Petrone - Mizuho Securities - Analyst : Very helpful. And pipeline, this is more of a totality question. Really when you look at the TETON programs with United and then you take 101 clofazimine, 201 in IPF, both you and your partner go for the same indication. And just looking at a blue sky scenario, that's a heck of a lot of REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 08, 2025 / 1:00PM, MNKD.OQ - Q1 2025 MannKind Corp Earnings Call Technosphere devices if it all comes to fruition. So just a recap on the Danbury capacity, if the blue sky scenario plays out over the next five years, would you need a growth CapEx injection? Thanks.

Question: Anthony Petrone - Mizuho Securities - Analyst : Thank you.